These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

987 related items for PubMed ID: 19758225

  • 1. Proliferation signal inhibitors for the treatment of refractory autoimmune rheumatic diseases: a new therapeutic option.
    Yoon KH.
    Ann N Y Acad Sci; 2009 Sep; 1173():752-6. PubMed ID: 19758225
    [Abstract] [Full Text] [Related]

  • 2. Practical use of immunosuppressive drugs in autoimmune rheumatic diseases.
    De Jesus A, Talal N.
    Crit Care Med; 1990 Feb; 18(2 Suppl):S132-7. PubMed ID: 2298028
    [Abstract] [Full Text] [Related]

  • 3. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X, Club Rheumatismes et Inflammation (CRI).
    Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
    [Abstract] [Full Text] [Related]

  • 4. Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation.
    Moro JA, Almenar L, Martínez-Dolz L, Sánchez-Lázaro I, Agüero J, Salvador A.
    Transplant Proc; 2008 Nov; 40(9):3034-6. PubMed ID: 19010183
    [Abstract] [Full Text] [Related]

  • 5. Bromocriptine in rheumatic and autoimmune diseases.
    McMurray RW.
    Semin Arthritis Rheum; 2001 Aug; 31(1):21-32. PubMed ID: 11503136
    [Abstract] [Full Text] [Related]

  • 6. Cyclosporine: therapeutic effects in rheumatic diseases.
    Amor B, Dougados M.
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):218-23. PubMed ID: 3289207
    [No Abstract] [Full Text] [Related]

  • 7. Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment.
    Ramos-Barrón A, Piñera-Haces C, Gómez-Alamillo C, Santiuste-Torcida I, Ruiz JC, Buelta-Carrillo L, Merino R, de Francisco AL, Arias M.
    Lupus; 2007 Jun; 16(10):775-81. PubMed ID: 17895299
    [Abstract] [Full Text] [Related]

  • 8. Autologous stem cell transplantation in autoimmune diseases.
    Passweg J, Tyndall A.
    Semin Hematol; 2007 Oct; 44(4):278-85. PubMed ID: 17961728
    [Abstract] [Full Text] [Related]

  • 9. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
    Sola E, Lopez V, Gutierrez C, Cabello M, Burgos D, Molina MG, Hernandez D.
    Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
    [Abstract] [Full Text] [Related]

  • 10. The development of inflammatory arthritis and other rheumatic diseases following stem cell transplantation.
    Barnabe CC, LeClercq SA, Fitzgerald AA.
    Semin Arthritis Rheum; 2009 Aug; 39(1):55-60. PubMed ID: 18519150
    [Abstract] [Full Text] [Related]

  • 11. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P, Salaffi F, Montecucco CM, Bombardieri S, Todesco S.
    Reumatismo; 2009 Aug; 61(2):132-9. PubMed ID: 19633800
    [Abstract] [Full Text] [Related]

  • 12. [Immunosuppressive therapy in autoimmune diseases].
    Schwarz-Eywill M.
    Z Arztl Fortbild Qualitatssich; 1999 Mar; 93(2):93-100. PubMed ID: 10355057
    [Abstract] [Full Text] [Related]

  • 13. Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient--not all proliferation signal inhibitors are the same: a case report.
    De Simone P, Petruccelli S, Precisi A, Carrai P, Doria R, Menichetti F, Filipponi F.
    Transplant Proc; 2007 Dec; 39(10):3500-1. PubMed ID: 18089420
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Withdrawal of proliferation signal inhibitors due to adverse events in the maintenance phase of heart transplantation.
    Gonzalez-Vilchez F, Vazquez de Prada JA, Almenar L, Arizon Del Prado JM, Mirabet S, Diaz-Molina B, Delgado JF, Gomez-Bueno M, Paniagua MJ, Perez-Villa F, Roig E, Martínez-Dolz L, Brossa V, Lambert JL, Segovia J, Crespo-Leiro MG, Ruiz-Cano MJ.
    J Heart Lung Transplant; 2012 Mar; 31(3):288-95. PubMed ID: 22133787
    [Abstract] [Full Text] [Related]

  • 17. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy.
    Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, Frigerio M, Lehmkuhl H, Marcen R, Morris R, Nashan B, Pascual J, Pohanka E, Segovia J, Zuckermann A.
    Transplant Proc; 2007 Dec; 39(10):2937-50. PubMed ID: 18089298
    [Abstract] [Full Text] [Related]

  • 18. [Antimalarial agents in rheumatic diseases. New therapeutic aspects of an old medication].
    Barthel HR, Meier LG, Wallace DJ.
    Dtsch Med Wochenschr; 1996 Dec 13; 121(50):1576-82. PubMed ID: 8998931
    [No Abstract] [Full Text] [Related]

  • 19. Everolimus-related pulmonary toxicity in heart transplant recipients.
    Expósito V, de Prada JA, Gómez-Román JJ, González-Vilchez F, Llano-Cardenal M, García-Camarero T, Fernández-Valls M, Ruano J, Martín-Durán R.
    J Heart Lung Transplant; 2008 Jul 13; 27(7):797-800. PubMed ID: 18582812
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.